Home   Business   Article

Subscribe Now

Fast-growing genomics company Broken String Biosciences sets up new home at Chesterford Research Park’s Science Village





Genomics company Broken String Biosciences has relocated its laboratory team to Chesterford Research Park’s Science Village.

It has taken Suite 8 following a seed funding round worth about £3million in September 2021.

Chesterford Research Park Science Village (55156207)
Chesterford Research Park Science Village (55156207)

The company aims to develop safer cell and gene therapies by assessing the stability of the genome, deploying novel genomic sequencing approaches to build a technology platform for the development of CRISPR cell and gene therapies.

INDUCE-seq, its core technology, is a DNA break mapping technology that assesses the specificity of genome editing approaches and evaluates the genetic risks associated with editing the genome.

A graduate of the Illumina Accelerator, the company originally set up at the BioData Innovation Centre on the Wellcome Genome Campus. In its new labs, it will undertake existing and new collaborations and proprietary R&D.

The team, which has doubled in size in three months, continues to grow.

Dr Felix Dobbs, CEO of Broken String Biosciences (55156205)
Dr Felix Dobbs, CEO of Broken String Biosciences (55156205)

CEO Dr Felix Dobbs said: “We are delighted to have opened our new laboratory at Science Village, Chesterford Research Park. The proximity to our headquarters at the Wellcome Genome Campus, and the excellent facilities on site, make it the ideal location for growing our laboratory team to develop INDUCE-seqTM and other technologies that will enable safe and sustainable cell and gene therapies for patients.”

Julian Cobourne, head of regional offices, Aviva Investors, joint owners of Chesterford Research Park with Uttlesford District Council, said: “I am thrilled that Broken String Biosciences has chosen Chesterford Research Park as the base from which to expand its laboratory operations.

The Nucleus at Chesterford Research Park (55156241)
The Nucleus at Chesterford Research Park (55156241)

“We are fully committed to forging ahead with our next phase of development, which, subject to planning, will include a 60,000 sq ft multi-occupier building fitted with a mix of laboratory and office space ready for occupation at the end of 2023.”

The park is already home to Arecor, AstraZeneca, Cambridge Epigenetix, Charles River Laboratories, Domainex, Illumina and Lonza.

Read more

Join the Cambridge Independent’s free marketing masterclasses and build your brand

Illumina Accelerator Cambridge announces four chosen genomics start-ups and £20m match-funding pledge



This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More